Pharm Flashcards
multidrug-resistant TB
TB resistant to INH and RIF
high risk for treatment failure and further acquired drug resistance
refer them to ID specialists and state health departments
extensive drug resistant TB
MDR (INH and RIF) plus resistance to FQN and at least one other injectable (amikacin, kanamycin, capreomycin)
relatively rare
cell wall comparison
inner leaflet of outer membrane composed of arabinogalactan and mycolic acids
outer leaflet is composed of extractable phospholipids
principles for TB treatment
use multiple drugs
prolonged treatment required for successful eradication
patients must be followed closely
therapeutic failure
positive sputum cultures after 4 months compliant therapy
goals of TB treatment
convert sputum cultures to negative
prevent the emergence of resistance
assure a complete cure without relapse
MOA rifampin
inhibits DNA dependent RNAP
suppression of initiation of chain formation in RNA synthesis
bactericidal-kills within macrophages and in caseating granulomas
synergism for rifampin
isoniazid
shortens course of therapy
distribution of rifampin
widely distributed
excellent tissue distribution
metabolism of rifampin
metabolized by deacetylation
autoinduction of metabolism occurs-maximum at 6 doses
adverse effects of rifampin
transient elevation in serum transaminases
hepatotoxicity (higher risk in alcoholics)
GI upset
hypersensitivity
discoloration of bodily fluids
drug interactions for rifampin
increase in P450 increased metabolism of warfarin theophylline narcotics oral hypoglycemics steroids (oral contraceptives)
place of rifampin in therapy
treatment of active TB
2nd line for preventative therapy
mechanism of action isoniazid
inhibits synthesis of mycolic acid
transported into bacterium-kills actively growing in extracellular, inhibits dormant organisms in macrophages and caseating granulomas
metabolism isoniazid
primarily by acetylation
monoacetyl hydrazine-important metabolite
source of hepatotoxic effects in isoniazid
hydroxylated to an electrophilic intermediate
rates of acetylation of isoniazid
slow or rapid acetylators
slow-higher chance of adverse reactions
Egyptians-slow
Eskimos and Japanese-rapid
elimination of isoniazid
elimination dependent on acetylator phenotype
adverse effects of isoniazid
transient elevation in serum transaminases
hepatotoxicity
neurotoxicity
hypersensitivity
avoiding neurotoxicity from isoniazid
pyridoxine (B6) to reduce incidence
particularly important in alcoholics, children, malnourished, slow acetylators
use of isoniazid in therapy
treatment of active TB
preventative therapy for patients with +PPD
mechanism of action for pyrazinamide
not documented
bactericidal toward dormant organisms in acidic environment within macrophages
metabolism of pyrazinamide
hydrolyzed in liver to active pyrazinoic acid
elimination of pyrazinamide
5-hydroxypyrazinoic acid excreted by kidneys
adverse effects of pyrazinamide
hepatotoxicity
hyperuricemia (decreased renal excretion)
GI upset
hypersensitivity (photosensitivity, rash)
mechanism of action for ethambutol
bacteriostatic
elimination of ethambutol
elimination of parent compound+inactive metabolite excreted in urine
adverse effects ethambutol
optic neuritis (decreased red-green acuity)
monitor every 4-6 weeks
use caution in young children
mechanism of action for streptomycin
aminoglycoside antibiotic
bactericidal through protein inhibition
inactive against intracellular organism
alternative to ethambutol
absorption of streptomycin
poorly absorbed in GI tract
administer IV or IM
adverse effects for streptomycin
nephrotoxicity (less than other aminoglycosides)
impairment of 8th cranial nerve function (vertigo>hearing)
pain on injection
second line agents
para-aminosalicylate ethionamide cycloserine capreomycin kanamycin amikacin
rifabutin
rifamycin derivative
used in TB patients who have experienced intolerance to rifampin or experiencing interactions
more active against MAC
adverse reactions to rifabutin
rash GI arthralgias myalgias discoloration of urine/sweat/tears neutropenia hepatotoxicity
requirements for rifapentine
with INH in continuation phase
must be HIV negative
must have non-cavitary, drug susceptible pulmonary TB with negative sputum smears at completion of initial phase of treatment
mechanism of action clofazamine
causes inhibition of transcription
used as an antileprosy agent
clofazamine adverse reactions
GI upset
severe and life threatening abdominal pain and organ damage from crystal deposition
discoloration of skin and eyes
macrolides in TB
unlikely to be effective against TB
clarithromycin and azithromycin against MAC
quinolones in TB
ciprofloxacin and ofloxacin effective against TB
RIPE or RIPS
use if >4% resistance
6 months for general TB treatment
avoid in renal failure
avoid streptomycin, kanamycin, and capreomycin
avoid in children
avoid ethambutol
suspected treatment failure
add >2 new TB agents
lepromatous leprosy
loss of specific cell mediated immunity
tuberculoid leprosy
strong cell mediated immunity
diagnosis of leprosy
acid-fast stain and cytologic examination of skin
response to lepromin skin test
treatment of leprosy
dapsone/rifampin/clofazimine
duration for 3-5 years
mechanism of action dapsone
competitive inhibitor of folic acid synthesis
inhibition of dihydropteroate synthase which prevents utilization of PABA
bacteriostatic
adverse reactions to dapsone
hemolytic anemia
hypersensitivity
MAI
symptoms usually when CD4 <100
prophylaxis at <50
fever, night sweats, weight loss, anemia
macrolides in MAC
clarithromycin better than azithromycin
usually one with ethambutol
inflammatory mechanism of asthma
increase mast cells, eosinophils, Th2 cells
increase histamine, D4, D2 in airway
inflammatory mechanism of COPD
increase neutrophils, macrophages, CD8T cells
role of space chamber
increase proportion of drug entering airway
used to decrease oropharyngeal deposition of inhaled corticosteroids
albuterol, levalbuterol
B2 agonist with quick onset
used to reverse asthma/bronchospasm
adverse effects of albuterol, levalbuterol
overuse indicates worsening asthma
airway tolerance
tremor, restlessness, tachycardia, hypokalemia
epinephrine MOA
A1, A2, B1, B2 agonist
adverse effects of epinephrine
palpitations, pale complexion, sweating, tremor, anxiety
adverse effects isoproterenol
cardiac stimulation
non-selective B agonist not used in US
salmeterol, formoterol, indacterol
long acting B2 agonists
uses for LABA
prophylaxis
not used in acute asthma attack
have to be given with inhaled corticosteroid
combination inhalers
more effective than corticosteroids or LABA alone
increase B2 receptor numbers
ipratropium, tiotropium
muscarinic receptor antagonists
do not cross BBB (quaternary amines)
ipra 4x, tio 2x
adverse effects ipratropium, tiotropium
bitter taste dry mouth glaucoma urinary retention paradoxical bronchospasm
methacholine
agonist that is used to diagnose bronchial airway hyperactivity in patients that have asthma
theophylline
weak inhibitor of PDE isoforms, bronchodilator, anti-inflammatory activity, inhibits A1
metabolism of theophylline
metabolized by p450
large variations in clearance (intra and inter-individual variability)
toxicity of theophylline
headache, nausea, vomiting and restlessness at low dose toxicity
high concentration-cardiac arrhythmias (PDE3), seizurs (A1)